Trial Profile
Phase 2b trial of inecalcitol as first-line therapy in patients with hormone-refractory prostate cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Inecalcitol (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Aug 2011 New trial record